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10% for head and neck and 4.5% for pancreas, in agreement 
with respective LEM-based prescription doses, adopted in our 
protocols. Deviations are expected to be close to zero around 
a prescription DRBE = 5 Gy (RBE). Target under-dosage was 
shown in LEM-based optimized plans, when uncorrected DRBE 
were prescribed.  
 
Conclusion: The delivery of a voxel by voxel iso-effective 
plan, if different RBE models are employed, is not feasible; it 
is however possible to minimize differences in dose deposited 
in the target. Dose prescription is a clinical task which 
ultimately depends only on the radiation oncologist clinical 
decision; in this study we made an attempt to avoid 
systematic errors which could potentially compromise tumor 
control. Initial clinical data on local control of adenoid cystic 
carcinoma treated in our facility confirms the validity of this 
approach. 
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Purpose or Objective: To assess clinical and dose factors 
affecting the incidence of urinary symptoms between 6 and 
24 months after therapy completion in patients treated with 
radical RT for prostate cancer. 
 
Material and Methods: This study examined the dataset of a 
prospective study with patients treated with conventional 
(74-80 Gy at 1.8-2 Gy/fr) or moderately hypofractionated RT 
(65-75.2 Gy at 2.2-2.7 Gy/fr) in 5 fractions per week. Clinical 
factors were collected for each patient: comorbidities, drugs, 
hormone therapies, previous surgeries, smoking, alcohol, 
age, and body mass index. Bladder DVHs were corrected with 
alfa/beta=3Gy. Urinary symptoms were evaluated through 
the IPSS (International Prostate Symptom Score) and ICIQ 
(International Consultation on Incontinence Modular 
Questionnaire short form) questionnaires filled in by the 
patients at start/end of RT and every 6 months until 5 years 
of follow up. We considered the sum of the 7 IPSS questions 
and the sum of questions 3-4 of ICIQ for the two endpoints: 1) 
IPSS≥15 and 2) ICIQ34>=4 at least once between 6 and 24 
months after RT. The best predictors to be included in the 
logistic regression model were identified through backward 
feature selections on 1000 bootstrap resamplings (the 
reported NArea identifies the weighted occurrences of the 
variables at the leading positions); then multivariate 
regressions on 1000 bootstrap resamplings were employed to 
compute the odds ratio distributions of the selected 
variables. 
 
Results: 539 patients were enrolled: dose parameters and 
toxicity data at baseline and between 6-24 months were 
available for 195 (IPSS) and 197 (ICIQ) patients. 158/195 
(81%) and 150/158 (95%) patients did not show toxicity at 
baseline (IPSS<=12 and ICIQ3=0, respectively). At 6-24 
months, the incidence of IPSS>=15 was 42/158 (27%) and of 
ICIQ34>=4 was 34/150 (23%). A 6-variable model (AUC=0.86) 
was considered for IPSS: basal IPSS (NArea=0.72, OR=1.51) 
and the change of IPSS at RT end (deltaIPSS) (NArea=0.74, 
OR=1.16) were the leading risk factors. V62Gy was also a risk 
factor (NArea=0.36, OR=1.04), while the analogues and 
antiandrogens in hormone therapies were found protective 
(NArea=0.34, OR=0.38) and risk parameters (NArea=0.29, 
OR=2.57), respectively. For ICIQ, a backward feature 
selection was employed: antiaggregants (OR=2.16, p=0.11), 
antiandrogens (OR=2.03, p=0.08) and age (OR=1.09, p=0.04) 
were found as risk factors, whereas none dose parameter was 
found correlated with toxicity. 
 
 
 
 
 
Conclusion: The analysis shows an important correlation of 
urinary toxicities at 6-24 months with the patient urinary 
condition at baseline and, also, with the acute worsening of 
symptoms. Interestingly, hormone therapies with analogues 
(protective) and antiandrogens (risk) showed an opposite 
behaviour for late toxicities. The absence of correlation of 
incontinence with dose might be due to the very low number 
of severe toxicities registered. 
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Purpose or Objective: Differential diagnosis between benign 
changes on follow-up CT from progression or recurrence is a 
difficult task in highly conformal RT because areas of dense 
consolidation usually develop around the treated tumor. The 
